Abstract: The present invention relates to a fragrance or flavor composition comprising a fragrance or flavor component acting on at least one olfactory receptor polypeptide selected from the group consisting of (a) OR2C1 and OR4Q3, and (b) polypeptides which comprise an amino acid sequence sharing an identity of at least 80% with the amino acid sequence of any of the polypeptides in (a) and which are responsive to at least one offensive odor-causing substance selected from the group consisting of trans-2-nonenal, trans-2-octenal, 1-octen-3-one, 1,5-octadien-3-one, 1-octen-3-ol and 1,5-octadien-3-ol to suppress the response intensity of the olfactory receptor polypeptide(s) to at least one of the offensive odor-causing substances, and also relates to a product comprising this fragrance or flavor composition and a method for suppressing offensive odors.

Abstract: The present invention relates to a fragrance composition containing a fragrance component which suppresses response strength of at least one olfactory receptor polypeptide, which is selected from the group consisting of OR2L3 and polypeptides that comprise an amino acid sequence having at least 80% identity to an amino acid sequence of OR2L3 and are responsive to an unpleasant odor-causing substance, to the unpleasant odor-causing substance. According to a preferred embodiment of the present invention, an unpleasant odor masking composition containing, as active components, at least one antagonist against an olfactory receptor OR2L3 and a specific component among fragrances which do not exert the effect of suppressing the response of OR2L3, is provided. According to a preferred embodiment of the present invention, unpleasantness caused by at least one unpleasant odor selected from the group consisting of fecal odor, body odor, tobacco odor, breath odor and musty odor can be reduced.

Abstract: To provide a compound which can be used as an MC4 receptor agonist. The present inventors have investigated MC4 receptor agonists, and have found that a piperazine derivative has an action related to the agonists, thereby completing the present invention. That is, the piperazine derivative of the present invention has an MC4 receptor agonistic action, and can be used as an agent for preventing or treating bladder and/or urinary tract diseases, in particular, underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethral relaxation failure, detrusor-external urethral sphincter dyssynergia, and voiding dysfunctions in benign prostatic hyperplasia.

Abstract: [Problem] To provide a compound which can be used as an MC4 receptor agonist. [Means for Solution] The present inventors have investigated MC4 receptor agonists, and have found that a piperazine derivative has an action related to the agonists, thereby completing the present invention. That is, the piperazine derivative of the present invention has an MC4 receptor agonistic action, and can be used as an agent for preventing or treating bladder and/or urinary tract diseases, in particular, underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethral relaxation failure, detrusor-external urethral sphincter dyssynergia, and voiding dysfunctions in benign prostatic hyperplasia.

Abstract: A compound which is useful as an active ingredient for a pharmaceutical composition for treating urine storage dysfunction, voiding dysfunction, lower urinary tract dysfunction, and the like. The present inventors have found that a 2-aminothiazole derivative has an excellent muscarinic M3 receptor-positive allosteric modulator activity and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, thereby completing the present invention. 2-aminothiazole derivative or a salt thereof of the present invention is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, for example voiding dysfunction such as underactive bladder.

Abstract: A compound which is useful as an active ingredient for a pharmaceutical composition for treating urine storage dysfunction, voiding dysfunction, lower urinary tract dysfunction, and the like. The present inventors have found that a 2-aminothiazole derivative has an excellent muscarinic M3 receptor-positive allosteric modulator activity and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, thereby completing the present invention. 2-aminothiazole derivative or a salt thereof of the present invention is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, for example voiding dysfunction such as underactive bladder.

Abstract: [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. In addition, the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound or a salt thereof of the present invention, and an excipient.

Abstract: [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. In addition, the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound or a salt thereof of the present invention, and an excipient.

Abstract: [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. In addition, the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound or a salt thereof of the present invention, and an excipient.

Abstract: [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. In addition, the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound or a salt thereof of the present invention, and an excipient.

Abstract: [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. In addition, the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound or a salt thereof of the present invention, and an excipient.

Abstract: The present invention provides a polarizing film or a polarizer that has an elastic modulus of at most about 3500 N/mm2 and suppresses occurrence of warping, the polarizing film is obtained by adsorbing a dichroic material in a polyvinyl alcohol-based film 20 ?m in thickness and stretching the tilin. The polarizing film has a transmittance of at least 43% and a polarization degree of at least 98%. A transparent protective layer is laminated on at least one surface of the polarizing film to form a polarizing plate.

Abstract: The present invention provides a polarizer and a polarizing plate having less dimensional changes to heat stress. The present invention provides also a liquid crystal display that includes the polarizer and the polarizing plate, and is free of color irregularity or decoloration. The polarizer has shrinkage force of not more than 4.0 N/cm in the absorption axis direction after being heated at 80° C. for 30 minutes. A protective film is laminated on at least one surface of the polarizer in order to form a polarizing plate, and the polarizing plate has a following relationship of 0.01?A/B?0.16 when A denotes a thickness of the polarizer and B denotes a thickness of the protective film.

Abstract: A polarizing plate having excellent moisture durability and a liquid crystal display using the same are disclosed. The polarizing plate is produced by covering all surfaces and sides of a polarizer with low moisture-permeable layers having moisture permeability of 310 g/m2·24 h or less. The rate of change in dimension of the polarizer in the uniaxially stretched direction is ±0.1% or less after left at a temperature of 60° C. and humidity of 95% for 100 hours.

Abstract: A polarizing plate used for manufacturing a liquid crystal display with suppressed irregularity in brightness, a method of manufacturing the same, and a liquid crystal display using the same, are provided. The polarizing plate is formed having a laminate of a polarizing film and a transparent protective layer provided on at least one surface of the polarizing film. By heat-treating and subsequently reheat-treating, the laminate has a shrinkage force of at most 8N/10 mm width when the laminate is further left at 60° C. for 1 hour, and furthermore, the laminate has a single hue value b of at most 4.6 NBS.

Abstract: A liquid crystal display comprising a liquid crystal display wide viewing angle polarizing adhesion film, which comprising a polarizing layer laminated on an optical compensation film and a retardation film and/or a brightness enhancement film laminated on said polarizing layer, wherein said polarizing layer is directly laminated on said optical compensation film, adhered onto at least one side of a liquid crystal panel, is less brightness nonuniformities.

Abstract: A polarizing plate and a liquid crystal display using the same are disclosed. The polarizing plate includes a polarizer made of a synthetic resin and protective films. The same protective films are attached to both sides of the polarizer. When a FTIR-ATR method is carried out with respect to the both sides of the protective film and a peak intensity (A) in the wavelength range around 1488 cm?1 of one side, a peak intensity (B) in the wavelength range around 1365 cm?1 of one side, a peak intensity (A?) in the wavelength range around 1488 cm?1 of another side and a peak intensity (B?) in the wavelength range around 1365 cm?1 of another side are measured, and (C) and (C?) are represented by the relationships: (A)/(B)=(C) and (A?)/(B?)=(C?), (C)/(C?)?1.2 is satisfied. The same sides of the protective films having the (C) and (C?) are adhered to both sides of the polarizer.

Abstract: A polarizing plate and a liquid crystal display using the same are disclosed. The polarizing plate includes a polarizer made of a synthetic resin and protective films. The same protective films are attached to both sides of the polarizer. When a FTIR-ATR method is carried out with respect to the both sides of the protective film and a peak intensity (A) in the wavelength range around 1488 cm?1 of one side, a peak intensity (B) in the wavelength range around 1365 cm?1 of one side, a peak intensity (A?) in the wavelength range around 1488 cm?1 of another side and a peak intensity (B?) in the wavelength range around 1365 cm?1 of another side are measured, and (C) and (C?) are represented by the relationships: (A)/(B)=(C) and (A?)/(B?)=(C?), (C)/(C?)?1.2 is satisfied. The same sides of the protective films having the (C) and (C?) are adhered to both sides of the polarizer.

Abstract: A polarizing plate having excellent moisture durability and a liquid crystal display using the same are disclosed. The polarizing plate is produced by covering all surfaces and sides of a polarizer with low moisture-permeable layers having moisture permeability of 310 g/m2·24 h or less. The rate of change in dimension of the polarizer in the uniaxially stretched direction is ±0.1% or less after left at a temperature of 60° C. and humidity of 95% for 100 hours.

Abstract: The present invention provides a polarizing film or a polarizer that has an elastic modulus of at most about 3500 N/mm2 and suppresses occurrence of warping, the polarizing film is obtained by adsorbing a dichroic material in a polyvinyl alcohol-based film 20 ?m in thickness and stretching the film. The polarizing film has a transmittance of at least 43% and a polarization degree of at least 98%. A transparent protective layer is laminated on at least one surface of the polarizing film to form a polarizing plate.